Asia-Pacific Interventional Cardiology Companies

Received CE Mark approval for its Amplify™ Flex Stent System, designed for improved deliverability and conformability in challenging coronary anatomies.Expanded its portfolio with the launch of the Aveiro™ Renal Denervation System for treating resistant hypertension, potentially offering a minimally invasive alternative to traditional therapies.Announced positive results from the TWENTE-4 trial demonstrating the safety and efficacy of its Ranger™ QBE PTA Balloon Catheter for treating peripheral artery disease.

Medtronic Introduced the Micra AVT™ transcatheter heart valve system offering a minimally invasive option for patients with severe aortic stenosis who are ineligible for traditional surgery.

Terumo Corporation Launched the WINEON™ Stent System featuring a unique design for optimal vessel wall apposition and improved clinical outcomes.Expanded its presence in the Asia-Pacific market through strategic partnerships and acquisitions.

List of Asia-Pacific Interventional Cardiology Key Companies in the Market

• Abbott Laboratories Inc. (U.S.)


• Braun Melsungen AG (Germany)


• R. Bard Inc. (U.S.)


• Abiomed Inc. (U.S)


• Edwards Lifesciences (U.S.)


• Biosensors International Group Ltd. ( Singapore)


• Boston Scientific Corporation (U.S.)


• Medtronic PLC (Ireland)


• Angiodynamics Inc. ( U.S)


• Terumo Medical Corporation (Japan)


• Johnson & Johnson Services Inc. (U.S.).


• Lombard Medical Technologies Plc. (U.K)


• Clearstream Technologies Group Plc. (Ireland)